Camlin Fine Sciences Limited has informed the Exchange about Update on Disclosure Made Pursuant To Clause 5 Of Para B Of Part A Of Schedule III Of SEBI LODR Regulations 2015.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 4.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences is extending the timeline to complete its majority stake acquisition of France-based Vinpai S.A. from June 30, 2025 to September 30, 2025. The delay is because the foreign sellers are still obtaining Indian PAN and demat accounts needed for the preferential allotment under SEBI rules. The company has already invested €3.3 million (approximately ₹30+ crore) in Vinpai via listed secured convertible bonds, whose maturity has also been pushed from six months to October 25, 2025. This is an update to the original announcement made on February 24, 2025. The deal itself is still on track, just delayed by procedural requirements on the sellers' side.
The acquisition is delayed by about three months due to administrative issues on the seller's side, not any deal-related problems. Shareholders should note the extended timeline but the deal remains active with €3.3 million already deployed. Minor short-term uncertainty but no material change to the strategic intent.